- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.11. | FDA grants fast track status to FELIQS's FLQ-101 to prevent ROP | ||
| 04.11. | Northwestern and Case Western Reserve universities develop Huntington's therapy | ||
| 01.11. | Lexicon stock tumbles after FDA AdCom votes against Zynquista again | ||
| 01.11. | Verastem Oncology submits NDA for ovarian cancer treatment | ||
| 01.11. | US court upholds Avadel's narcolepsy drug approval amid exclusivity battle | ||
| 01.11. | AbbVie and EvolveImmune Therapeutics sign oncology collaboration | ||
| 01.11. | EC fines Teva $502m over multiple sclerosis treatment Copaxone practices | ||
| 31.10. | Matinas BioPharma mulls wind-down as antifungal therapy deal falls through | ||
| 31.10. | Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight | ||
| 31.10. | Reeves' 2024 budget promises life sciences investment | ||
| 31.10. | Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions | ||
| 30.10. | Will the tide turn for the wave of pharma layoffs? | ||
| 30.10. | How a patient helped shape a treatment for rare skin disorder | ||
| 30.10. | Pfizer boasts over 30% increase in Q3 revenues against previous year | ||
| 30.10. | For pharma companies, the possibilities of green chemistry are huge | ||
| 30.10. | ARIA-E risk of Lilly's Kisunla in Alzheimer's reduced with modified dosing | ||
| 30.10. | Spero's stock slides after antibiotic flops in Phase II trial | ||
| 30.10. | IDWeek 2024: Kalihinol analogue shows promise as targeted antimalarial therapy | ||
| 30.10. | Novartis' Scemblix gains FDA approval for leukaemia | ||
| 30.10. | GSK to acquire Chimagen's CMG1A46 for autoimmune disease | ||
| 29.10. | Dermavant acquisition expands Organon's dermatology portfolio | ||
| 29.10. | Bavarian eyes Mpox vaccine label expansion to include toddlers, kickstarts Phase II trial | ||
| 29.10. | US Border Protection warns pharma of risks with incorrect biologic importation | ||
| 29.10. | EC approves AstraZeneca's Fasenra for EGPA treatment | ||
| 29.10. | South Korean pricing reform suggests more flexible drug reimbursement negotiations |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
